300558.SHE Betta Pharmaceuticals Co Ltd

300558.SHE trades 169.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

No fundamental analysis for Betta Pharmaceuticals Co Ltd yet.

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug …

2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.

Betta Pharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)

Dividend yield

0.78%

Forward dividend

0.15 CNY

Payout ratio

49.4%

Ex-dividend date

Jun 9, 2026

From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.

Company name

Betta Pharmaceuticals Co Ltd

Ticker

300558.SHE

ISIN

CNE100002DD9

Exchange

Shenzhen Stock Exchange

Sector

Healthcare

Industry

Pharmaceuticals

Employees

1,785

Fiscal year end

December

Address

No. 355, Xingzhong Road, Hangzhou, China, 311100

Phone

86 571 8613 0357

Website

bettapharma.com

About Betta Pharmaceuticals Co Ltd

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal cancer, and other solid tumor indications. It also develops BPI-D0316, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutation; EYP-1901, an investigational long-acting treatment for wet AMD, non-proliferative diabetic retinopathy, diabetic macular edema, and pmCNV; and MCLA-129, a bispecific antibody targeting both EGFR and c-Met. In addition, the company develops BPI-371153 for the treatment of patients with locally advanced or metastatic solid tumor or relapsed/refractory lymphoma; CFT8919, an in vitro and in vivo model of EGFR L858R-driven NSCLC; and Balstilimab, a human monoclonal antibody targeting programmed cell death protein 1 and an immune checkpoint inhibitor. Further, it develops a recombinant human serum albumin injection under the OsrHSA name; and products for the treatment of solid tumor under the BPI-452080, MRX2843, BPI-460372, BPI-221351, BPI-520105, BPI-572270, and BPI-585725 names. The company was founded in 2003 and is headquartered in Hangzhou, China.

• Dr. Lieming DingFounder, Chairman of the Board, CEO & GM · born 1963
• Ms. Jia TongCEO & Director · born 1977
• Mr. Jianxun FanVP, CFO & Director · born 1971
• Mr. Jiang WanSenior VP, President of Global Sales & Director · born 1968
• Dr. Mao LiPresident of R&D, Chief Medical Officer & Director · born 1957
• Mr. Shi Zhe DingDirector & Assistant to the Chairman · born 1991
• Hena ShiVP, COO & General Manager of Oncology Business Department